Milestone Pharmaceuticals Inc.
HealthcareNASDAQ:MIST · NASDAQ Global Select
+$0.00 today
Vol 0.68M · Avg 2.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-151.0%
avg -107.3%
ROIC
-62.0%
avg -53.7%
ROA
-55.5%
avg -48.6%
Analysis
ROA is currently the strongest return metric at -55.5% versus its period average of -48.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph G. Oliveto | Chief Executive Officer, President & Director | $931,384.00 | — | 58 | $77,000.00 | 0.09% |
David Bharucha FACC | Chief Medical Officer | $664,417.00 | — | 64 | $0.00 | <0.01% |
Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development | $631,860.00 | — | 53 | $204,000.00 | 0.24% |
Lorenz Muller | Chief Commercial Officer | $397,534.00 | — | 62 | $204,000.00 | 0.24% |
Philippe Douville | Founder, Strategic Advisor & Member of Scientific Advisory Board | — | — | 64 | $43,392.00 | 0.05% |
Guy Rousseau | SVP of Regulatory Affairs and Quality Management | — | — | — | — | — |
Philip T. Sager FACC FAHA FHRS | Chief Medical Advisor & Member of the Scientific Advisory Board | — | — | 70 | — | — |
Jeff Moore | Vice President of Sales | — | — | — | — | — |
Jeff Nelson | Chief Operating Officer | — | — | 45 | $204,000.00 | 0.24% |
Roshan Girglani | Vice President of Marketing | — | — | — | — | — |
Anita Holz | Vice President & Head of Medical Affairs | — | — | — | — | — |
David Sandoval | General Counsel & Chief Compliance Officer | — | — | 48 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$1.18M
Net Sentiment
$1.18M
Net selling
Most Active
Oliveto Joseph
5 transactions
1–10 of 13
Analysis
Insiders reported 0 buys worth $0.00 and 13 sells worth $1.18M over the last 12 months. That adds up to net selling of $1.18M. Oliveto Joseph was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +39.9% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +39.9% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages MIST?
Milestone Pharmaceuticals Inc. (MIST) lists 12 active executives. The top listed executive is Joseph G. Oliveto, Chief Executive Officer, President & Director.
Are MIST insiders buying or selling?
Recent insider activity shows net buying of $27.55M.
Explore More
Continue the stock analysis
Jump to another research area for this company.